IMMUCELL CORP /DE/

IMMUCELL CORP /DE/ insiders are currently net buyers of ICCC stock, showing bullish sentiment over the past 90 days. Executives have purchased $2.2M while selling $168.2K, resulting in a positive net flow of $2.0M. This buying activity represents 93% of total transaction volume.

IMMUCELL CORP /DE/ has 16 active insiders who have filed SEC Form 4 transactions in the past 90 days. Norman H. Pessin (Executive) leads with 1 transactions totaling $892.5K. David Scott Tomsche (Executive) follows with 116 transactions worth $717.2K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. IMMUCELL CORP /DE/'s current score of 93/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $2.2M in purchases versus $168.2K in sales.

The most recent insider transaction occurred on Mar 20, 2026, when F. Brigham Michael (Executive) disposed of 25,000 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ICCC insider trading sentiment is currently bullish with an Alignment Score of 93/100. The net insider flow of $2.0M reflects accumulation, with 93% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like IMMUCELL CORP /DE/. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ICCC, we track all Form 4 filings—currently showing 457 transactions from 16 insiders over 90 days.

A 10b5-1 plan allows IMMUCELL CORP /DE/ executives to pre-schedule stock sales when they don't possess material non-public information. At ICCC, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ICCC appears discretionary, making insider signals more meaningful.

You can monitor IMMUCELL CORP /DE/ (ICCC) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 16 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. IMMUCELL CORP /DE/'s current score of 93/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $2.2M in purchases versus $168.2K in sales over 90 days, resulting in a net flow of $2.0M.

SEC Form 4 filings are mandatory reports that IMMUCELL CORP /DE/ insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ICCC, the most common type is "D" with 33 occurrences. The most recent Form 4 was filed on Mar 20, 2026 by F. Brigham Michael.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At IMMUCELL CORP /DE/, approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ICCC represents discretionary decisions with more informational value.